autodesk preview au takeaway
thought manag meet maintain outperform
analyst day takeaway posit long haul
note new custom acquisit
primari metric quarter
solid tone
note meet troy rohrbaugh head global
color fundament focu call
manag meet offer insight price model reiter
nexobrid bla file
europ strategi track
quarterli updat hbv rsv spotlight
analyst certif import disclosur see
beat consensu demand remain healthi fy revenu
datatim nov like continu gain
quick read bright spot result
autodesk preview au takeaway
expect result least meet like exceed consensu growth profit estim autodesk
report result next tuesday attend autodesk univers week conduct survey autodesk
custom overal end-market demand product look strong industri backlog appear healthi
balanc detect construct industri custom less optimist outlook ntm anticip slow
growth trend follow period strong growth past year bottom line continu believ
posit take share larg digit replatform opportun current disrupt construct industri
drive good growth cash gener futur
report earn tuesday morn host call et expect oct sales/ep compar favor
street expect modest downsid consensu jan sales/ep given lack
pronounc rebound industrial/auto trim estim ahead earn hpa peer point
gener demand stabil lean channel though hope v-shape recoveri clearli materi global pmi
dip may remain neg macro/geopolit uncertainti persist see top hpa
beneficiari next year though near-term peer highlight modest slowdown deploy moder ahead
spend ramp longer term like adi divers exposur across industrial/auto/comm industri lead gm/om/fcf
thought manag meet maintain outperform
manag remain focus growth effici gain announc detail on-demand product
next week launch year-end anticip radic alter gross margin profil scale
single-incid offer core warranti busi current round price increas complet believ
manag trade price increas retent gain given updat assumpt higher increment
invest spend less aggress price increas lower ebitda maintain outperform
sustain growth resourc optim
analyst day takeaway posit long haul
emerg past cycl posit deliv market outgrowth higher level profit vein
compani analyst day highlight multipl lever core market outgrowth medium-term well near-term
action manag cycl time compani re-affirmed commit sustain invest next-gen
diesel altern powertrain technolog latter occur somewhat crowd space nascent market
demand former creat opportun share gain watch potenti relat catalyst
full guidanc come earn call lower estim item provid maintain
note new custom acquisit primari metric quarter
recent met investor meet discuss outlook pharmaceut busi takeaway includ
recent merck kgaa collabor one four big pharma prospect referenc call none
convert yet ten next custom run rang pilot studi small project matur time greater
emphasi potenti cell therapi compani increment reduct emphasi neoantigen cancer vaccin
compar earlier discuss pipelin skew toward research-stag program lastli expect introduct
companion diagnost support evolutionari chang product mix rather transform shift toward recur clinic
solid tone
thur nov host small group client senior manag
compani corpor offic springfield missouri
look quit favor upon auto part servic sector owe solid strengthen sale
backdrop signific defens threat on-line competit still accommod share valuat
repres one best oper within broader space
manag discuss busi trend intra-quart compani report sep result oct
overal found tone manag upbeat construct walk away encourag compani
continu capit well upon solid intern execut solid industri backdrop
takeaway manag indic clearli posit confluenc factor creat favor demand
trend within space includ normal car parc season weather healthi spend part core
mid-to-low incom consum optimist toward long-term prospect recent announc acquisit
mexico plan continu evalu prospect chain tariff factor help
deliv long await return healthi modest price inflat within space on-line competit within auto part retail
remain quit subdu given natur product sold signific servic compon do-it-yourself difm
busi continu manag well wage inflat forese signific relief long
strong macro backdrop continu propel healthi job growth employ level
note meet troy rohrbaugh head global market
chanc meet troy rohrbaugh head global market equiti ficc trade room
small group institut investor mani question meet seem steadili revert back two
consist theme perhap small set competitor scale beget scale
doubt chang someday immedi visibl futur hard see way present environ low
neg rate low volatil flat industri wallet particularli relat ficc
color fundament focu call
manag meet offer insight price model reiter nexobrid bla file
recent met mdwd manag investor meet discuss progress toward file bla nexobrid
price metric commerci launch nexobrid mid potenti leverag barda studi acceler earli
hospit adopt time enrol first patient phase ii escharex studi expect nexobrid gener
near-term newsflow includ potenti procur contract barda next month
see greater upsid potenti escharex develop base larg vlu dfu patient roughli
nexobrid opportun separ updat financi outlook base measur outlook growth
effect today acut spin-off trade independ entiti ticker baudax
mission develop commerci innov therapeut hospit relat acut care set anticip
us approv launch lead candid anjeso iv meloxicam manag moderate-to-sever acut pain
see differenti non-opioid analges least sale opportun could achiev
commerci effort requir addit capit support develop earli yet interest
pipelin asset may partner outperform price target retain outperform
contract develop manufactur organ pt
europ strategi track
aeri announc european commiss grant market author rhokiinsa netarsudil reduct
elev intraocular pressur adult patient primari open-angl glaucoma oag ocular hypertens oht
note import step obtain futur approv fix dose combin product roclanda netarsudil/
latanoprost eu manag anticip file approv model roclanda launch late
revenu reach outer year view eu market highli competit maintain
outperform rate pt
quarterli updat hbv rsv spotlight
report quarterli financi result includ quarterli hcv royalti in-lin
estim consensu estim quarterli ep
consensu estim busi updat highlight includ rsv adult out-pati initi top-
line data expect nash readout featur stat sig liver fat reduct mri-pdff
expect initi follow-on fxr liver/gi specif distribut expect
initi studi hbv healthi volunt top-lin expect updat
model actual detail full report publish today
follow check var us europ believ least meet street revenu
expect y/i driven balanc product subscript revenu growth yoy
respect check suggest on-going strength america region off-set stabil european
region continu invest vs challeng yoy european region comp believ next-gen secur product
prisma aim secur cloud cortex offer aim secur futur leverag ai/ml capabl
propel growth longer term estim remain intact maintain outperform rate pt
beat consensu demand remain healthi fy revenu guidanc tweak higher
oct post revenu y/i vs quarter
made sever signific announc includ receipt fedramp author moder impact level
gener servic administr fedramp program manag offic introduct multipl new offer
includ new version splunk enterpris splunk enterpris secur launch splunk ventur
fund design fuel next gener data analyt acquisit omnit stealth-mod saa compani
streamlio open-sourc distribut messag leader rise demand data-driven insight continu drive
perform compani platform posit leverag data prolifer revenu growth reiter
outperform target
sustain growth resourc optim
attend autom fair analyst day wednesday opportun experi
view integr cohes roadmap help rockwel custom captur valu connect
enterpris given align technolog custom readi believ rockwel posit gain
market share core discret autom offer expand address market integr solut
expand presenc process hybrid applic broader geograph reach immun macro
believ rockwel technolog solut best-of-bre partnership deep domain expertis well align benefit
secular it/ot converg trend view reflect stock current valuat
pure results/outlook disappoint stronger expect price headwind continu weigh sale macro pressur
also grown slow sale process given magnitud miss poor visibl expect share
come sharp nt pressur range-bound visibl improv said comfort outperform
rate thesi lt see support solid new custom activ fast pace product/tam expans potenti repurchas
activ strategi quickli adapt hybrid/multi-cloud world also silver-lin nand pressur
drive strong product gm support bottom-lin leav us favor lt risk/reward outlook maintain
datatim nov like continu gain cloud market share
fcc announc c-band public auction
microsoft slack dau sinc juli
join us aw reinvent
file anti-trust case softbank-own firm patent practic reuter
promis new architectur adopt intel tick-tock model digitim
quick read bright spot result
overal look favor upon oct result updat jan guidanc
report yesterday nov market close oct solid sale potteri barn west elm continu
impress cost control off-set top-line weak store albeit less sever degrad
gross margin increasingli optimist follow year reinvest process improv
oper margin like bottom await signal improv gross margin consist broad-
base sale turn construct share
sustain growth resourc optim
tsla cyberturck unveil hotli anticip expect debat design equal heat
consum love angular design anticip major consum inspir vehicl differ
current norm perform spec impress rel tsla primari pick-up competit rivian tow
payload capac mix versu configur premium price deliveri indic begin
late expect investor continu focu model capac ramp sale china along
model ramp primari stock driver near term would expect share fade announc investor
like skeptic broad consum adopt cybertruck
adjust ep y/i top estimate/consensus/guid predomin
on-line track metric grew y/i pace well vs guidanc consumer/strateg
segment season light total revenu grew y/i respect guid total revenu
exist consensu adjust ep exist consensu pre-tax season market spend overal compani
maintain guidanc metric feel slightli conserv consid out-performance
conserv maintain reiter outperform target
dec cloud summit aw inventla vega nv
may biotech summit featur chemistri life process institutechicago
